| Scientific Presentations | ||||
|---|---|---|---|---|
| Initial Phase 3 Studies Results for Rilonacept in the Prevention of Gout Flares | Jun 9, 2010 |
|
532.3 KB | |
| Financial Presentations | ||||
|---|---|---|---|---|
| Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference Presentation | Aug 13, 2010 |
|
1.7 MB | |
Stock Information
| NASDAQ:REGN
$23.17 + 0.69 |
Sep 2, 2010
11:30 AM ET |
Quotes delay at least 20min., by eSignal.
